Gavi, the Vaccine Alliance announced that it had signed a Statement of Intent with Sanofi and GSK to provide 200 million doses of the companies’ adjuvanted recombinant protein COVID-19 vaccine to the COVAX Facility.
The non-binding statement is a critical step toward making sure doses of the vaccine, if approved and licensed, will be made available to all countries and economies participating in the COVAX Facility.
CEO of Gavi said, “The signing of this statement of intent is an important step forward in our partnership, and I welcome Sanofi and GSK’s commitment to the COVAX goal of equitable access to COVID-19 vaccines. Gavi is seeking to secure doses of the most promising vaccine candidates – so that the 184 participants involved in the COVAX Facility can make sure their most at-risk groups, such as healthcare workers, have rapid access to doses of a safe and effective vaccine. That is the world’s best chance to end the acute stage of this pandemic, and we encourage other vaccine manufacturers to work with us towards that shared global goal.”
Gavi is coordinating the design and implementation of the COVAX Facility, a global mechanism which seeks to procure, equitably allocate and deliver 2 billion doses of safe and effective COVID-19 vaccines by the end of 2021.
92 higher-income economies have already signed up as self-financing members of the Facility, joining 92 low-and middle-income economies who will have their participation supported by the Gavi COVAX AMC.